Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Rifaximin Versus Lactulose in Renal Failure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by Weill Medical College of Cornell University.
Recruitment status was:  Recruiting
Information provided by:
Weill Medical College of Cornell University Identifier:
First received: September 8, 2008
Last updated: January 3, 2011
Last verified: January 2011
The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

Condition Intervention Phase
Liver Cirrhosis
Renal Failure
Drug: Rifaximin
Drug: Lactulose
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure

Resource links provided by NLM:

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • slower progression to severe hepatic encephalopathy, stage 3 or 4 [ Time Frame: during hospitalization ]

Estimated Enrollment: 70
Study Start Date: June 2008
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
35 patients receiving rifaximin
Drug: Rifaximin
400 mg orally
Other Name: Xifaxin, Salix Pharmaceuticals
Experimental: B
35 patients receiving lactulose
Drug: Lactulose
20 grams titrate to 2-3 bowel movements in one day


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • cirrhosis of liver of any etiology
  • progressive renal failure
  • stage 0-2 hepatic encephalopathy

Exclusion Criteria:

  • pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00748904

Contact: Samuel Sigal, MD 212-746-4129
Contact: Amy Tilara, MD 646-713-7284

United States, New York
Weill Cornell Medical Center Recruiting
New York, New York, United States, 10021
Contact: Samuel Sigal, MD    212-746-4129   
Contact: Amy Tilara, MD    646-713-7284   
Principal Investigator: Samuel Sigal, MD         
Sub-Investigator: Amy Tilara, MD         
Sub-Investigator: Ilan Weisberg, MD         
Sub-Investigator: Melanie Starcic, PA         
Sponsors and Collaborators
Weill Medical College of Cornell University
  More Information

Responsible Party: Samuel Sigal, Center for Liver Diseases and Transplantation Identifier: NCT00748904     History of Changes
Other Study ID Numbers: 0801009635
Study First Received: September 8, 2008
Last Updated: January 3, 2011

Keywords provided by Weill Medical College of Cornell University:
cirrhosis of liver and progressive renal failure

Additional relevant MeSH terms:
Renal Insufficiency
Liver Cirrhosis
Pathologic Processes
Kidney Diseases
Urologic Diseases
Liver Diseases
Digestive System Diseases
Gastrointestinal Agents
Anti-Infective Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents processed this record on May 24, 2017